Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Viral Vectors And Plasmid DNA Manufacturing Market Forecast: What Market Value Is Expected By 2030?

The market for viral vectors and plasmid DNA production has experienced substantial expansion recently, projected to increase from $7.11 billion in 2025 to $8.79 billion in 2026, signifying a compound annual growth rate (CAGR) of 23.7%. This remarkable growth trajectory during the historical period is largely attributable to burgeoning gene therapy research, the broadening scope of vaccine development efforts, amplified funding for academic and clinical investigations, the initial commercial success of cell therapies, and significant progress in molecular biology methodologies.

Exponential expansion is projected over the coming years for the market encompassing viral vectors and plasmid DNA, with an anticipated surge to $20.36 billion by 2030, driven by a compound annual growth rate of 23.4%. This predicted growth trajectory is fueled by a confluence of factors, including a greater number of gene and cell therapy approvals, escalating requirements for large-scale commercial production, the broadening of collaborations with contract manufacturing organizations (CMOs), a heightened concentration on treating rare diseases, and ongoing advancements aimed at improving vector design and manufacturing efficiency. Key developments anticipated during this period involve the wider implementation of adaptable viral vector production systems, increased utilization of single-use bioprocessing technologies, a growing need for superior purity plasmid DNA, the scaling up of contract manufacturing capabilities, and a more intense focus on production processes that adhere to regulatory standards.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20690&type=smp

Viral Vectors And Plasmid DNA Manufacturing Market Expansion Supported By Key Demand Factors

The burgeoning field of gene therapies is poised to significantly boost the viral vectors and plasmid DNA manufacturing sector in the coming years. Gene therapy, a medical approach focused on modifying an individual’s genetic makeup to address or avert illness, benefits immensely from increased investment in biotech research and development, coupled with a deeper comprehension of the genetic and cellular processes involved in diverse diseases. The production of viral vectors and plasmid DNA is critical for effectively transporting therapeutic genes into patient cells, thereby allowing for the molecular-level correction of genetic conditions. Illustrating this trend, the American Society of Gene & Cell Therapy reported that the number of gene therapies progressing through Phase III clinical trials experienced a 10% rise in the third quarter of 2023, marking the initial quarterly expansion since the third quarter of 2022. Consequently, the growing pipeline of gene therapies is a primary catalyst for the expansion of the viral vectors and plasmid DNA manufacturing market.

Viral Vectors And Plasmid DNA Manufacturing Market Segmentation Trends And Revenue Drivers

The viral vectors and plasmid dna manufacturing market covered in this report is segmented –

1) By Product Type: Plasmid Deoxyribonucleic Acid (DNA), Viral Vector, Non-Viral Vector

2) By Scale Of Operation: Preclinical, Clinical, Commercial

3) By Therapeutic Area: Oncological Disorders, Rare Diseases, Neurological Disorders, Sensory Disorders, Metabolic Disorders, Musculoskeletal Disorders, Blood Disorders, Immunological Disorders, Other Disorders

4) By Application Area: Gene Therapies, Cell Therapies, Vaccines

5) By Type Of Manufacturer: In-house Manufacturers, Contract Manufacturing Organizations

Subsegments:

1) By Plasmid Deoxyribonucleic Acid (DNA): Linear Plasmid DNA, Circular Plasmid DNA, High-Copy Plasmid DNA, Low-Copy Plasmid DNA

2) By Viral Vector: Adenoviral Vectors, Lentiviral Vectors, Adeno-Associated Viral Vectors (AAV), Retroviral Vectors

3) By Non-Viral Vector: Liposome-Based Vectors, Polymer-Based Vectors, Nanoparticle-Based Vectors, Electroporation-Based Vectors

Viral Vectors And Plasmid DNA Manufacturing Market Growth Trends Influencing Competitive Dynamics

Strategic alliances are a key focus for major players in the viral vectors and plasmid DNA manufacturing sector, aimed at bolstering their production facilities, refining their technical expertise, and expediting the creation and market release of gene therapies worldwide. Through these cooperative ventures, companies can pool their resources and shared infrastructure, thereby elevating total manufacturing output to address the escalating need for gene therapies. An illustrative example occurred in June 2024 when Charles River Laboratories International Inc., a US provider of preclinical and clinical contract research services, entered into an agreement with Captain T Cell, a spin-off entity from Berlin’s esteemed Max Delbrück Center in Germany, to establish a production program for plasmid DNA and retroviral vectors. This partnership grants Captain T Cell entry to established contract development and manufacturing organization (CDMO) competencies and consultative assistance, simultaneously intending to speed up the progression from initial research phases to clinical testing for an innovative TCR-T cell therapy designed for solid tumors.

Viral Vectors And Plasmid DNA Manufacturing Market Industry Leaders: Which Organizations Are Driving Competition?

Major companies operating in the viral vectors and plasmid dna manufacturing market are Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, Catalent Inc., Revvity Inc., Wuxi Biologics Inc., FUJIFILM Diosynth Biotechnologies, Miltenyi Biotec GmbH, Aldevron LLC, Takara Bio Inc., Poseida Therapeutics Inc., RegenxBio Inc., Cobra Biologics, Finvector Vision Therapies Limited, Batavia Biosciences B.V., uniQure N.V., Addgene Inc., BioNTech IMFS GmbH, Creative Biogene Inc., Genezen Laboratories Inc., Virovek Incorporation, Waisman Biomanufacturing, Axplora GmbH

Access The Complete Viral Vectors And Plasmid DNA Manufacturing Market Report:

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-manufacturing-global-market-report

Viral Vectors And Plasmid DNA Manufacturing Market Regional Outlook: Where Are The Largest Opportunities Located?

North Americawas the largest region in the viral vectors and plasmid DNA manufacturing market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the viral vectors and plasmid dna manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model